Phase 1/2 Study Exploring the Safety, Tolerability, and Efficacy of INCAGN01876 Combined With Immune Therapies in Advanced or Metastatic Malignancies
Incyte Corporation
Incyte Corporation
Instituto do Cancer do Estado de São Paulo
Memorial Sloan Kettering Cancer Center
Molecular Templates, Inc.
Incyte Corporation